About Bowel Cancer Targeted-Therapies-Erbitux-770
At what stage is this treatment used?
  • Cetuximab is used as a first or second-line treatment option for patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type advanced (metastatic) colorectal cancer in combination with chemotherapy.  Cetuximab can also be given as a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy.
  • Before you are prescribed cetuximab, your doctor will test your cancer cells to see if they contain either the normal (wild-type) or mutant forms of genes called RAS.  Cetuximab is used to treat patients who express normal (wild-type) RAS genes. 
Treatment Erbitux
Is this drug available via the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
  • Cetuximab is PBS-subsidised as a treatment in combination with first-line chemotherapy of a patient with RAS wild-type metastatic bowel cancer who does not have progressive disease.

  • Cetuximab is PBS-subsidised as monotherapy or in combination with an irinotecan based therapy, of a patient with a WHO performance status of 2 or less and with RAS wild type metastatic bowel cancer after failure to respond to first-line chemotherapy.  The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.  

  • Patients who have progressive disease on panitumumab are not eligible to receive PBS-subsidised cetuximab.  Patients who have developed intolerance to panitumumab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised cetuximab.

Download the Consumer Medicine Information (CMI) for Cetuximab